A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Rheumatoid Arthritis
A Phase 2, Randomized, Double-blind, Placebo Controlled Multicenter Study of DDY391 Assessing Efficacy, Safety and Tolerability in Participants With Rheumatoid Arthritis
The purpose of this Phase 2 study is:
- to evaluate the efficacy, safety and tolerability of DDY391 in participants with moderate to severe active rheumatoid arthritis (RA).
- to provide information about dose selection and study design for subsequent clinical development.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy, safety, and tolerability of DDY391 in adult participants with active moderate to severe rheumatoid arthritis. The study will enroll participants with an inadequate response (IR) and/or intolerance (INT) to 1-2 bDMARD, with different mechanisms of action (MoA), or with IR or INT to one prior JAKi.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Novartis Pharmaceuticals
- Phone Number: +41613241111
- Email: novartis.email@novartis.com
Study Contact Backup
- Name: Novartis Pharmaceuticals
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Key Inclusion Criteria:
- Diagnosis of RA for at least 6 months prior to screening according to the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria.
- Moderate to severe RA at screening.
- Participants must be a rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide antibody (anti-CCP) positive at screening as assessed by central laboratory.
Key Exclusion Criteria:
- Presence of inflammatory conditions other than RA including but not limited to those associated with arthralgia or arthritis (e.g., psoriatic arthritis, systemic lupus erythematosus, scleroderma, sarcoidosis) or presence of active fibromyalgia or osteoarthritis with articular symptoms.
- Participants with ACR functional class IV.
- Previous treatment with any direct cell-depleting therapies, including but not limited to anti-CD20, unless ≥ 12 months prior to baseline.
- History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system within the past 5 years (except for basal cell carcinoma or actinic keratosis that have been treated with no evidence of recurrence in the past 3 months, carcinoma in situ of the cervix or non-invasive malignant colon polyps that have been removed).
- Active viral, bacterial or other infections requiring systemic treatment at the time of screening or randomization, or history of recurrent clinically significant infection or of recurrent bacterial infections.
Other protocol-defined inclusion/exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: DDY391 - Dose A
Participants will receive DDY391 Dose A. |
DDY391 |
|
Experimental: DDY391 - Dose B
Participants will receive DDY391 Dose B. |
DDY391 |
|
Experimental: Placebo
Participants will receive matching placebo. |
Matching placebo |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants achieving American College of Rheumatology 50 (ACR50) response
Time Frame: Week 12
|
To evaluate the efficacy of DDY391 versus placebo through achievement of ACR 50. |
Week 12
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline in disease activity score 28 C-reactive protein (DAS28-CRP)
Time Frame: Week 12
|
To evaluate the efficacy of DDY391 versus placebo through DAS28 CRP. |
Week 12
|
|
Incidence and severity of treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time Frame: through Week 16
|
Number of participants with AEs and SAEs, including changes in vital signs, electrocardiograms (ECGs) and laboratory values qualifying and reported as AEs. |
through Week 16
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CDDY391D12201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.